Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Audientes: focused strategy and initial funding in place

Company Announcement 18-2023May 31, 2023 Audientes A/S (CVR 36047631) today announces that it has secured a new convertible loan of DKK 750,000 from existing lenders as part of its strategy focused largely on the Indian market.Focused strategy: Audientes has formulated and have begun to execute on a highly focused strategy with its new exclusive partner Earkart in India as focal point. This translates to an opportunity to reach break-even in operations with total financing of less than DKK 5 million due to a cost-optimized operational approach. With this, Audientes will be fully

Notice of delisting

The bankruptcy estate of DOF ASA has been notified by Oslo Børs that Oslo Børs intends to delist DOF ASA from Oslo Børs due to the fact that bankruptcy proceedings have been opened in DOF ASA and the company no longer satisfy the conditions for listing. As previously informed, all of the subsidiaries in the DOF group have been acquired by DOF Group ASA, which is the new holding company in the group. The business of the DOF group is thus not affected by the bankruptcy in DOF ASA nor will it be affected by a delisting of DOF ASA from Oslo Børs.

Hamlet Pharma secures a new Alpha1H production batch for continued clinical trials

Lund, May 31, Hamlet Pharma soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections,  announces that Hamlet Pharma has secured the production of larger quantities of Alpha1H. The new batch will be essential to extend the clinical trial program in patients with bladder cancer.Hamlet Pharma is manufacturing the drug candidate Alpha1H for clinical trials in collaboration with Rechon Life Science AB. The production of a new batch has now been completed according to GMP (Good Manufacturing Practice)

Strand Kapitalförvaltning selects Sharpfin for a full coverage wealth management solution

Sharpfin continues to gain market shares by delivering their Wealth Management Suite to Strand Kapitalförvaltning (Strand), a leading Swedish independent Wealth Manager.Sharpfin provides Strand Kapitalförvaltning with a solution to support all aspects of their wealth management process. This includes an efficient module for client onboarding with automatic monitoring of PEP and AML and a powerful portfolio and order management solution with model portfolios and rebalancing. In addition to this, the solution also features a fee management module which calculates management fees down to daily

Amendment of yearly coupon for NORDEN bonds issued 28 june 2021

ANNOUNCEMENT NO. 110 - 31 MAY 2023  Not for release, publication or distribution, directly or indirectly, in any jurisdiction in which such release, publication or distribution would be unlawful At 1 July 2023 the coupon on senior unsecured bonds issued 28 June 2021 (announcement no. 70/21) will change from LIBOR + 4.75% to SOFR +5.01161%.   Listing prospectus of 14 October 2021 is attached to this company announcement together with Amendment Agreement at 1 July 2023. Both documents are also available from www.norden.com.   The securities offered by Dampskibsselskabet

Change in number of shares and votes in Ependion AB

As per May 31, 2023, the total number of shares in Ependion AB amounts to 29,241,296, divided into 28,941,216 ordinary shares and 300,080 class C shares, corresponding to a total of 28,971,224 votes.The change in number of shares and votes is due to the conversion of 103,789 class C shares, which previously have been issued and repurchased within the context of the company’s incentive program LTI 2020/2023, into ordinary shares during the month of May. The number of ordinary shares has thus increased by 103,789 shares and the number of class C shares has decreased by as many shares.

Cereno Scientific publishes an additional document in conjunction with admission to trading on Nasdaq First North Growth Market

Cereno Scientific AB ("Cereno Scientific" or the "Company") publishes an additional document (the “Document”) in conjunction with the first day of trading on Nasdaq First North Growth Market ("Nasdaq First North"), which is scheduled for June 14, 2023. The Document supplements, in accordance with Nasdaq First North’s rulebook, the prospectus published by Cereno Scientific on May 5, 2023 (the “Prospectus”).The Document is to be read as a supplement to the Prospectus that the Company disclosed in connection with the recently completed rights issue which ended on May 24, 2023. The Document

P CAPITAL ANNOUNCES NAV OF P CAPITAL PARTNERS IV

Press release Stockholm, 31 May 2023 Since P Capital Partners IV AB decreased its contributed capital by EUR 10 million through a repayment to debenture holders and owners, the Net Asset Value of the P Capital Partners IV AB participation loan has been calculated. The Net Asset Value is to be calculated at the close of each quarter and in conjunction with a capital increase or decrease. The repayment amounted to EUR 3.00 per Series A participation loan debenture and EUR 0.036 million to the owners.   At the close of business on 30 May 2023, the Net Asset Value of the P

SyntheticMR Receives Regulatory Approval for their Innovative SyMRI Software Solution in South Korea

SyntheticMR announced today that their quantitative imaging software solution SyMRI 12.1 has received regulatory approval in South Korea according to KFDA (Korea Food & Drug Administration). This means that SyMRI 12.1 now can be sold and distributed in this market.“This approval for SyMRI 12.1 creates vital opportunities for us to develop our market presence in South Korea, which is one of our focus markets. We already have an established customer base in the region” says Ulrik Harrysson, CEO at SyntheticMR. “We have also seen a growing interest for our products in the region, which is very

Share capital and number of ordinary shares in JM AB (publ)

In accordance with the resolution by the Annual General Meeting (AGM) on March 30, 2023, the share capital has been reduced for allocation of SEK 3,774,001 to unrestricted equity through the elimination of 3,774,001 own ordinary shares. The share capital of SEK 68,278,841 remains unchanged since the AGM resolved on a bonus issue, without the issue of new shares and through a transfer from unrestricted equity to share capital, at the same time as it resolved to reduce the share capital through the elimination of own ordinary shares. The share capital was thus restored to the same level as

Change in the number of shares and votes in Medivir AB (publ)

Stockholm – Medivir AB (publ) (“Medivir”) (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May 2023 as a result of the previously announced share issue of 970,500 shares of series C and the reclassification of 105,750 shares of series C into ordinary shares, which was carried out as part of the long-term incentive program for key employees within the Medivir group adopted by the annual general meeting held on 4 May 2023. As of 31 May 2023, the total number of shares in Medivir amounts to 56,706,151 of which 55,841,401 are

A-ROSA adds e-bikes on A-ROSA SENA

Plus, complimentary e-bike hire now available on A-ROSA fleetRostock, 31 May 2023 – A-ROSA has introduced e-bikes on A-ROSA SENA for the first time, including two bikes for teenagers. The move means that e-bikes are now available across 12 ships in its fleet, covering the Danube, Rhine, Main, Moselle, Seine and Rhone/Saone. In addition, A-ROSA has also introduced complimentary e-bike hire this year. This means that in selected ports guests now have the options to take an e-bike out for a spin independently, create their own route and explore a city or town on two wheels as they wish.

Fourth cohort completed in Aptahem’s FIH study

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today the completion of an additional cohort in the ongoing double-blinded randomized placebo controlled clinical First in Human (FIH) study.During the course of the study, there have been signs of interesting effects on clinical markers. Therefore, before starting the next cohort, extended analyses will be performed to gain a greater understanding of Apta-1’s clinical significance. These analyses will form an important basis for the further clinical

Risk Intelligence A/S and a major Norwegian Offshore Operator sign a deal for the Risk Intelligence System and bespoke intelligence support

Risk Intelligence A/S (“Risk Intelligence” or "the Company") and a high-profile Norway based offshore operator have signed an agreement giving access to the Risk Intelligence System as well as bespoke operational intelligence support.The agreement will provide the Norwegian client with enhanced situational awareness as their operations expand to new areas, supporting renewable and traditional energy projects - via Risk Intelligence’s cloud-based tool. Risk Intelligence will also provide bespoke port security assessments, area threat assessments and voyage risk assessments, ensuring that the

BioStock Life Science Spring Summit with Initiator Pharma

Do not miss Initiator Pharma’s presentation at the BioStock Life Science Spring Summit, today May 31 at 12.10. The event starts at 10.00 - see the full programme on BioStock's website  or YouTube channel .CEO Claus Elsborg Olesen will present Initiator Pharma at the BioStock Life Science Spring Summit , starting at 12.10.  This is a press release from BioStock – Connecting Innovation & Capital (

Project status update: First phase of offshore installation Dragon 12 completed in Vestmanna, Faroe Islands

Minesto, leading ocean energy developer, has today successfully completed the first phase of Dragon 12 (1.2 MW) offshore installation in Vestmanna, Faroe Islands. The 3.4 km main subsea cable was laid on the seabed, from the onshore grid connection point to the offshore installation node.After transit across the North Atlantic Ocean to Vestmanna, the cable installation work was commenced and was successfully completed today. The cable installation was completed in a 22-hour operation. “This cable is the highest valuable component of the infrastructure, and it’s a major milestone to have

Nowhere Networks brings high speed internet to the European cruise industry

The land-based maritime high-speed internet leader Nowhere Networks expands its offering with a complete vessel solution for internet at gigabit speeds in ports. In response to demand from the cruise industry Nowhere Networks already delivers Gbps speed in 50 European major ports today, soon to be expanded to 100 ports across the continent.In only a few years Nowhere Networks has built the world's largest land-based network for the maritime industry. After initially having focused on ferries in regular traffic Nowhere Networks is ready to offer the cruise industry an internet connection of

BioStock Life Science Spring Summit with Bioservo Technologies

Do not miss Bioservo Technologies presentation at the BioStock Life Science Spring Summit, today May 31 at 11.00. The event starts at 10.00 - see the full programme on BioStock's website  or YouTube channel .CEO Petter Bäckgren will present Bioservo Technologies at the BioStock Life Science Spring Summit , starting at 11.00.  This is a press release from BioStock – Connecting Innovation & Capital (

There are no items matching the current filter
There are no more items matching the current filter
Back to top